Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Author's Avatar
Mar 25, 2022

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for the quarter and year ended December 31, 2021 and provided an update on its business strategy and corporate progress.